Generalized Anxiety Disorder Clinical Trial
Official title:
Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)
Anxiety disorders are among the most common mental disorders in children, affecting approximately 1 out of every 10 children and adolescents. Symptoms of anxiety disorders may include excessive fear/anxiety/worry, somatic complaints such as headaches and muscle aches, and impaired social and family relationships. Some children with anxiety also experience sleep problems, however, little is known about the sleep patterns of anxious children. The purpose of the study, conducted at Children's National Medical Center, is to examine the sleep characteristics of children with Generalized Anxiety Disorder (GAD) compared to a control group of children without GAD to see how sleep behaviors and daytime behaviors are related.
Anxiety disorders are among the most common mental disorders in children, affecting
approximately 1 out of every 10 children and adolescents. Symptoms of anxiety disorders may
include excessive fear/anxiety/worry, somatic complaints such as headaches and muscle aches,
and impaired social and family relationships. Some children with anxiety also experience
sleep problems, however, little is known about the sleep patterns of anxious children. The
purpose of the study, conducted at Children's National Medical Center, is to examine the
sleep characteristics of children with Generalized Anxiety Disorder (GAD) compared to a
control group of children without GAD to see how sleep behaviors and daytime behaviors are
related.
To qualify for this study, participants must first be evaluated via a brief, telephone
screening. Qualified families will be invited for a comprehensive diagnostic interview. All
parents and children must sign a written consent/assent in order to participate.
Two groups of children are being recruited: children diagnosed with (a primary diagnosis of)
GAD and matched, healthy controls. To be included in the GAD group, children must:
- Meet DSM-IV criteria for a primary diagnosis of generalized anxiety disorder (GAD)
- Be between the ages of 7 and 11 years old
- Not take any psychotropic medications
- Not have any chronic/major medical problems
- Be of (at least) average intelligence (i.e., IQ of 80 or greater)
- Not meet criteria for psychosis, bipolar, or major depressive disorder
- Parents and children must be English speaking
To be included in the control group, children must:
- Not meet criteria for a psychiatric or sleep disorder
- Be between the ages of 7 and 11 years old
- Not take any psychotropic medications
- Not have any chronic/major medical problems
- Be of (at least) average intelligence (i.e., IQ of 80 or greater)
- Parents and children must be English speaking
Participation is voluntary. Families who choose to participate will be asked to make two
visits to Children's National. During their first visit, children and caregivers will be
asked to complete self- and parent-report forms, as well as diagnostic interviews. Children
will also be administered an abbreviated intelligence test. During their second visit, which
is an optional component of the study, participants (and one parent) will stay overnight at
Children's National and children will undergo an overnight sleep (polysomnographic)
evaluation. Between these visits, participants will wear wrist actigraphs for seven days. An
actigraph is a small device that looks like a watch and measures sleep and wake periods.
Families will be called daily during this week-long assessment and administered a brief
phone-based assessment regarding children's anxiety symptoms. Participants will receive some
compensation for time and travel.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |